InflaRx to Release 2025 Financial Results on May 7
InflaRx to Release First Quarter 2025 Results
InflaRx N.V. (NASDAQ: IFRX), a pioneering biopharmaceutical company based in Germany, is gearing up to report its financial and operational results for the first quarter of 2025 on May 7, 2025, prior to the opening of the market. This report is anticipated to provide insight into the company's performance and developments in the field of anti-inflammatory therapeutics.
About InflaRx N.V.
Founded in 2007, InflaRx specializes in developing innovative therapies that target the complement system to mitigate inflammation. Utilizing their advanced anti-C5a and anti-C5aR technologies, InflaRx aims to create highly potent inhibitors that specifically engage with C5a, an integral inflammatory mediator in numerous disease processes.
The company’s flagship product candidate, vilobelimab, is an intravenously administered, first-in-class monoclonal antibody that shows promise by selectively binding to free C5a. It has displayed significant clinical activity across various studies without major safety concerns, marking a promising advancement in treating inflammatory diseases.
Moreover, InflaRx is also working on INF904, a small molecule designed for oral administration that acts as an inhibitor of the C5a receptor. This indicates their commitment to offering versatile treatment options for patients suffering from inflammatory conditions.
Corporate Structure
InflaRx operates through its wholly owned subsidiaries, InflaRx GmbH located in Germany, and InflaRx Pharmaceuticals Inc. in the USA. With offices in Jena and Munich, Germany, as well as Ann Arbor, MI, the company strategically positions itself to advance its research and development while staying connected with both European and U.S. markets.
Company Contact Information
If you have inquiries regarding InflaRx or require further assistance, you can reach out directly to their investor relations team:
InflaRx N.V.
Jan Medina, CFA
Vice President, Head of Investor Relations
Email: IR@inflarx.de
MC Services AG
Katja Arnold, Laurie Doyle, Dr. Regina Lutz
Email: inflarx@mc-services.eu
Europe: +49 89-210 2280
U.S.: +1-339-832-0752
Frequently Asked Questions
What is the date for InflaRx’s financial report?
InflaRx will report its Q1 2025 financial results on May 7, 2025.
What is the main focus of InflaRx as a company?
InflaRx focuses on developing therapies targeting the complement system to treat inflammatory diseases.
What is vilobelimab?
Vilobelimab is InflaRx’s lead product candidate, an anti-C5a monoclonal antibody that has shown significant therapeutic activity.
Where is InflaRx headquartered?
InflaRx is headquartered in Jena, Germany, with additional offices in Munich and Ann Arbor, Michigan.
How can I contact InflaRx for investor relations?
Investors can contact Jan Medina at InflaRx via email at IR@inflarx.de for inquiries related to investor relations.
About The Author
Contact Caleb Price privately here. Or send an email with ATTN: Caleb Price as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
